BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 7710909)

  • 1. The role of protein kinase C in multidrug resistance.
    O'Brian CA; Ward NE; Gravitt KR; Fan D
    Cancer Treat Res; 1994; 73():41-55. PubMed ID: 7710909
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical reversal of multidrug resistance.
    Sikic BI; Fisher GA; Lum BL; Brophy NA; Yahanda AM; Adler KM; Halsey J
    Cancer Treat Res; 1994; 73():149-65. PubMed ID: 7710904
    [No Abstract]   [Full Text] [Related]  

  • 3. In vitro models of multiple drug resistance.
    Greenberger LM; Cohen D; Horwitz SB
    Cancer Treat Res; 1994; 73():69-106. PubMed ID: 7710911
    [No Abstract]   [Full Text] [Related]  

  • 4. In vivo models of P-glycoprotein-mediated multidrug resistance.
    Gottesman MM; Mickisch GH; Pastan I
    Cancer Treat Res; 1994; 73():107-28. PubMed ID: 7710902
    [No Abstract]   [Full Text] [Related]  

  • 5. Biology of the multidrug resistance-associated protein, MRP.
    Loe DW; Deeley RG; Cole SP
    Eur J Cancer; 1996 Jun; 32A(6):945-57. PubMed ID: 8763335
    [No Abstract]   [Full Text] [Related]  

  • 6. Overexpression of P-glycoprotein in heat- and/or drug-resistant hepatoma variants.
    Pirity M; Hevér-Szabó A; Venetianer A
    Cytotechnology; 1996; 19(3):207-14. PubMed ID: 8862008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Doxorubicin-resistant variants of human prostate cancer cell lines DU 145, PC-3, PPC-1, and TSU-PR1: characterization of biochemical determinants of antineoplastic drug sensitivity.
    David-Beabes GL; Overman MJ; Petrofski JA; Campbell PA; de Marzo AM; Nelson WG
    Int J Oncol; 2000 Dec; 17(6):1077-86. PubMed ID: 11078791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. P-glycoprotein--a mediator of multidrug resistance in tumour cells.
    Germann UA
    Eur J Cancer; 1996 Jun; 32A(6):927-44. PubMed ID: 8763334
    [No Abstract]   [Full Text] [Related]  

  • 9. Transporter molecules in multidrug resistance.
    Scheper RJ; Scheffer GL; Flens MJ; van der Valk P; Broxterman HJ; Izquierdo MA
    Cytotechnology; 1996; 19(3):187-90. PubMed ID: 8862005
    [No Abstract]   [Full Text] [Related]  

  • 10. Role of gene amplification in drug resistance.
    Schoenlein PV
    Cancer Treat Res; 1994; 73():167-200. PubMed ID: 7710905
    [No Abstract]   [Full Text] [Related]  

  • 11. Unanswered questions about multidrug resistance.
    Beck WT
    Cytotechnology; 1996; 19(3):177-9. PubMed ID: 8862003
    [No Abstract]   [Full Text] [Related]  

  • 12. Altered activity of MDR-reversing agents on KB3-1 cells transfected with Gly(185)-->Val human P-glycoprotein.
    Watanabe T; Uchiyama N; Roninson IB; Cohen D; Atadja P
    Int J Oncol; 2000 Sep; 17(3):579-86. PubMed ID: 10938401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemosensitisation of spontaneous multidrug resistance by a 1,4-dihydropyridine analogue and verapamil in human glioma cell lines overexpressing MRP or MDR1.
    Abe T; Koike K; Ohga T; Kubo T; Wada M; Kohno K; Mori T; Hidaka K; Kuwano M
    Br J Cancer; 1995 Aug; 72(2):418-23. PubMed ID: 7640227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circumvention of P-glycoprotein-mediated multiple drug resistance by phosphorylation modulators is independent of protein kinases.
    Smith CD; Zilfou JT
    J Biol Chem; 1995 Nov; 270(47):28145-52. PubMed ID: 7499304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversal of P-glycoprotein-mediated multidrug resistance in vitro by AV200, a new ardeemin derivative.
    Méndez-Vidal C; Quesada AR
    Cancer Lett; 1998 Oct; 132(1-2):45-50. PubMed ID: 10397452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multidrug resistance in human cancer.
    Goldstein LJ; Pastan I; Gottesman MM
    Crit Rev Oncol Hematol; 1992; 12(3):243-53. PubMed ID: 1353966
    [No Abstract]   [Full Text] [Related]  

  • 17. Evaluation of the clinical relevance of the expression and function of P-glycoprotein, multidrug resistance protein and lung resistance protein in patients with primary acute myelogenous leukemia.
    Tsimberidou AM; Paterakis G; Androutsos G; Anagnostopoulos N; Galanopoulos A; Kalmantis T; Meletis J; Rombos Y; Sagriotis A; Symeonidis A; Tiniakou M; Zoumbos N; Yataganas X
    Leuk Res; 2002 Feb; 26(2):143-54. PubMed ID: 11755464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular diagnosis of multidrug resistance.
    Herzog CE; Bates SE
    Cancer Treat Res; 1994; 73():129-47. PubMed ID: 7710903
    [No Abstract]   [Full Text] [Related]  

  • 19. Evidence for a constitutive, verapamil-sensitive, non-P-glycoprotein multidrug resistance phenotype in malignant glioma that is unaltered by radiochemotherapy in vivo.
    Rieger L; Rieger J; Winter S; Streffer J; Esser P; Dichgans J; Meyermann R; Weller M
    Acta Neuropathol; 2000 May; 99(5):555-62. PubMed ID: 10805101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anticancer drug-mediated induction of multidrug resistance-associated genes and protein kinase C isozymes in the T-lymphoblastoid cell line CCRF-CEM and in blasts from patients with acute lymphoblastic leukemias.
    Beck JF; Brügger D; Brischwein K; Liu C; Bader P; Niethammer D; Gekeler V
    Jpn J Cancer Res; 2001 Aug; 92(8):896-903. PubMed ID: 11509123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.